Clinical trials: Luminal B, active
Breast Adenocarcinoma, Luminal B Breast Cancer
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas
RATIONALE: The primary treatment for estrogen receptor-positive breast cancer relies on estrogen receptor inhibitors. However, responses to hormonal therapy can vary significantly, especially in luminal B breast cancer…
- Trial name
- H/ACA-ER (NCT06805084)
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
To determine whether short-term pre-operative nivolumab either as monotherapy or in combination with low dose doxorubicin or novel IO combinations can induce immune activation in early BC.
- Trial name
- BELLINI (NCT03815890)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Radiotherapy
Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer
IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost…
- Trial name
- NCT05673304
- Testing
- SBRT anticipated boost
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes
This is a translational study in patients with operated early breast cancer of Luminal A or Luminal B sub types.The Hellenic Cooperative Oncology Group (HeCOG) has designed an observational biomarker-driven study in patients with…
- Trial name
- NCT04403984
- Where
- Greece
- Volunteers
- 750 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)
PhActHealth is a multicenter randomized controlled trial enrolling women with newly diagnosed luminal B or triple-negative breast cancer (BC) who are candidates for neoadjuvant therapy.
- Trial name
- PhActHealth (NCT07776951)
- Testing
- Pre-habilitation exercise program
- Where
- 2 sites in Italy
- Volunteers
- 126 people
- Sponsor
- University of Milan
Breast Neoplasms, Triple Negative Breast Neoplasms
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments.
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
- Trial name
- NCT07856225
- Testing
- CDK4/6 Inhibitors, Anti-HER2 Therapy, Standard Breast Cancer Treatment
- Where
- Colombia
- Volunteers
- 370 people
- Sponsor
- Fundación Santa Fe de Bogota
Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases
The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity of chemotherapy using weekly paclitaxel (arm A) versus the combination of the cdk 4/6 inhibitor palbociclib and standard endocrine treatment (arm B).
- Trial name
- PREDIX LumB (NCT02603679)
- Testing
- Paclitaxel, Tamoxifen + Palbociclib, Aromatase Inhibitor + Palbociclib
- Where
- 3 sites in Sweden
- Volunteers
- 181 people
- Sponsor
- Thomas Hatschek
Luminal B
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1.
- Trial name
- Neo-CheckRay (NCT03875573)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Oleclumab
- Where
- 7 sites in Belgium, France
- Volunteers
- 147 people
- Sponsor
- Jules Bordet Institute
Metastatic Breast Cancer
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and…
- Trial name
- OCDMBC (NCT07704801)
- Testing
- CDK4/6 inhibitors
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Sohag University
Breast Cancer Female
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare.
- Trial name
- XenoBreast (NCT04133077)
- Testing
- blood samples collection
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Centre Jean Perrin